KAM
SRPT icon

Kazazian Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Kazazian Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$257K – 51
2025
Q2 		$257K Buy
+15,000
New +$640K 0.35% 39
2017
Q4 		– Sell
-5,832
Closed -$265K – 85
2017
Q3 		$265K Buy
+5,832
New +$233K 0.32% 58
2015
Q3 		– Sell
-4,419
Closed -$134K – 104
2015
Q2 		$134K Sell
4,419
-10,634
-71% -$217K 0.13% 55
2015
Q1 		$200K Sell
15,053
-3,929
-21% -$52.4K 0.26% 48
2014
Q4 		$275K Buy
+18,982
New +$321K 0.24% 53

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kazazian Asset Management's SRPT Position: Q3 2025 in Review

Kazazian Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 15,000 shares — an estimated $257K sold.

Kazazian Asset Management first reported a position in SRPT in Q4 2014 and held it in 5 quarters. The position peaked at $275K in Q4 2014. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Kazazian Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 15,000 Sarepta Therapeutics shares in Q3 2025, an estimated $257K.
  • Kazazian Asset Management first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 5 quarters.
  • Kazazian Asset Management's Sarepta Therapeutics position peaked at $275K in Q4 2014.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Kazazian Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.